Compare Allegion PLC (ALLE) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allegion PLC vs Novo Nordisk A/S — how do they compare? Allegion PLC trades at $165.82 (market cap $14.32B), while Novo Nordisk A/S trades at $46.44 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 14.5× Allegion PLC's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| ALLE | NVO | |
|---|---|---|
Market Cap | $14.32B | $207.85B |
Sector | Industrials | Health |
52-Week High | $179.77 | $63.98 |
52-Week Low | $125.65 | $35.29 |
Enterprise Value | $16.03B | $222.55B |
Dividend Yield | 1.26% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALLE trades at $166.18, up 0.39% on the day, showing strong momentum following better-than-expected Q2 2026 earnings. The stock demonstrates robust fundamentals with 15.36% net income margin and 33.73% ROE, though recent quarters show mixed earnings performance. Technical indicators suggest bullish momentum with the current price near resistance levels. Recent institutional buying and positive analyst coverage highlight growing confidence in the security products provider's growth trajectory.
Outlook remains positive with raised 2026 guidance and strong Americas segment performance driving optimism. Investment opportunity lies in continued margin expansion and market share gains, while risks include international segment weakness and rising input costs. The stock trades above consensus price target but offers potential upside to high target of $170.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
